TELA Bio, Inc. announced that it has appointed Doug Evans, the President and Chief Executive Officer of Lungpacer Medical Inc., and Lisa Colleran, a principal of LNC Advisors, LLC, to its board of directors effective April 20, 2020. As part of this announcement, Doug Evans will also assume the Chairman of the Board of Directors role from Kurt Azabarzin, who will continue to serve as an independent board member. Furthermore, current board members Ashley Friedman, Matt Zuga, and Ron Ellis will be stepping down. Following these changes, TELA Bio's board will be composed of seven directors, six of whom are independent. Ms. Colleran will serve on the Company’s Audit Committee, which will consist of Ms. Colleran, Mr. Evans and Federica O’Brien, as chairperson, and the Company’s Nominating and Corporate Governance Committee, which will consist of Ms. Colleran and Adele Oliva, as chairperson. Mr. Evans will serve as chairperson of the Board and on the Company’s Audit Committee and the Company’s Compensation Committee, which will consist of Kurt Azarbarzin, Mr. Evans and Vince Burgess, as chairperson. On April 20, 2020, Ronald Ellis, Ashley Friedman and Matthew Zuga, each members of the Board of Directors (the “Board”) of TELA Bio, Inc. (the “Company”), notified the Company of their intentions to step down from their positions as a members of the Board and respective committees of the Board, effective April 20, 2020. None of Messrs. Ellis, Freidman or Zuga’s decisions to resign resulted from any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO, INC. 
